Jupiter Asset Management Ltd. Purchases 1,846,907 Shares of Elanco Animal Health Incorporated $ELAN
Jupiter Asset Management Ltd. significantly increased its stake in Elanco Animal Health (NYSE:ELAN) by 98.8%, acquiring an additional 1,846,907 shares to own a total of 3,716,849 shares valued at approximately $74.9 million. This move is complemented by insider buying, with CEO Jeffrey N. Simmons and Rajeev A. Modi purchasing shares, suggesting internal confidence. The company currently holds a "Moderate Buy" consensus rating from Wall Street analysts, with several firms raising their price targets.
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Elanco Animal Health (NYSE:ELAN) Stock
JPMorgan Chase & Co. raised its price target for Elanco Animal Health (NYSE:ELAN) to $28 from $24, maintaining an "overweight" rating and suggesting a 12.7% upside. This follows a trend of bullish sentiment among analysts, with the company holding a "Moderate Buy" consensus and an average price target of $25.89. Insider activity also shows confidence, as the CEO and other insiders recently purchased over 43,000 shares.
Elanco to Participate in Upcoming Investor Conferences
Elanco Animal Health Incorporated announced its management will participate in several upcoming investor conferences in February and March 2026. Executives including CEO Jeff Simmons and CFO Bob VanHimbergen will be featured in fireside chats at events such as the BofA Animal Health Summit, TD Cowen Health Care Conference, Barclays Global Healthcare Conference, Leerink Global Healthcare Conference, and KeyBanc Capital Markets Healthcare Forum. Live audio webcasts of these events will be available on Elanco's investor relations website.
Five live Elanco investor talks set through March 17, 2026
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in five investor conferences between February 26 and March 17, 2026. Executives including Jeff Simmons, Bob VanHimbergen, Luke Smith, and Bobby Modi will engage in fireside chats at events hosted by BofA, TD Cowen, Barclays, Leerink, and KeyBanc Capital Markets. Live audio webcasts and replays of these sessions will be available on Elanco's investor relations website.
Countdown to Elanco Animal Health (ELAN) Q4 Earnings: Wall Street Forecasts for Key Metrics
Wall Street analysts predict Elanco Animal Health (ELAN) will report Q4 earnings of $0.11 per share, a 21.4% decline year-over-year, with revenues reaching $1.09 billion, up 7.1%. Key metric forecasts include $477.11 million for Total Pet Health, $12.17 million for Total Contract Manufacturing, and $602.04 million for Total Farm Animal revenue. Analysts also project geographical revenues of $511.93 million for the U.S. and $572.02 million for International, with ELAN currently holding a Zacks Rank #3 (Hold).
Companion Animal Health Market Set for Explosive Growth to US$ 56.60 Billion by 2033, Led by North America's 36.53% Market Share | Key Players - Zoetis, Elanco, Merck Animal Health
The global companion animal health market is projected to reach US$56.60 billion by 2033, up from US$25.38 billion in 2024, driven by rising pet ownership, humanization trends, and advancements in veterinary care. North America currently leads the market, although the Asia-Pacific region is experiencing the fastest growth. Key players like Zoetis, Elanco, and Merck Animal Health are introducing innovative products and technologies to meet the increasing demand for pet pharmaceuticals, diagnostics, and preventive care.
Animal Performance Enhancers Market Forecast Through 2026-2033: Emerging Trends, Market Drivers, and Strategic Insights Revealed in New Study | Zoetis • Elanco Animal Health • Merck Animal Health
A new report by Coherent Market Insights forecasts substantial growth for the Animal Performance Enhancers Market from 2026 to 2033, driven by increasing strategic initiatives from major players. The report provides a comprehensive analysis of market trends, drivers, challenges, and the competitive landscape, including key players like Zoetis, Elanco Animal Health, and Merck Animal Health. It offers insights into market segmentation, geographical landscapes, and factors influencing growth, aiming to provide businesses with data-driven strategies.
Illinois Municipal Retirement Fund Sells 100,254 Shares of Elanco Animal Health Incorporated $ELAN
The Illinois Municipal Retirement Fund significantly reduced its stake in Elanco Animal Health Incorporated, selling 100,254 shares and now owning 87,219 shares valued at $1.76 million. Despite this, other institutional investors increased their holdings, and company insiders also purchased shares. Analysts have a "Moderate Buy" consensus rating for ELAN, with an average target price of $25.44.
Northwestern Mutual Investment Management Company LLC Buys Shares of 110,738 Elanco Animal Health Incorporated $ELAN
Northwestern Mutual Investment Management Company LLC initiated a new position in Elanco Animal Health Incorporated (NYSE:ELAN) during the third quarter, acquiring 110,738 shares valued at approximately $2.23 million. Other institutional investors like HSBC and Norges Bank also significantly increased their stakes, bringing total institutional ownership to 97.48%. Company insiders recently bought 43,450 shares, and Elanco maintains a "Moderate Buy" consensus rating from Wall Street analysts with a target price of $25.44.
Elanco Animal Health (ELAN) to Release Earnings on Tuesday
Elanco Animal Health (ELAN) is scheduled to release its Q4 2025 earnings before market open on Tuesday, February 24th, 2026. Analysts are forecasting earnings per share of $0.11 and revenue of $1.094 billion. The stock currently holds a "Moderate Buy" consensus rating from Wall Street analysts, with a target price of $25.44.
Board Exits at Elanco (ELAN) Raise a Quiet Question About Future Innovation and Oversight Balance
Elanco Animal Health (ELAN) announced that two long-serving directors, R. David Hoover and Dr. Deborah Kochevar, will not seek re-election, marking a significant governance transition. Hoover was the founding Chairman, and Kochevar led the Innovation, Science, and Technology committee, raising questions about the future balance of innovation and corporate oversight. Investors are advised to consider how these departures might influence Elanco's growth assumptions, especially given existing concerns about debt, margins, and upcoming Q4 2025 earnings.
Rhumbline Advisers Grows Position in Elanco Animal Health Incorporated $ELAN
Rhumbline Advisers significantly increased its stake in Elanco Animal Health (NYSE:ELAN) by 190.5% in the third quarter, now owning 1,319,770 shares valued at $26.58 million. Institutional investors collectively own 97.48% of the company, and recent insider buying has also occurred. Elanco currently trades around $25 with a market cap of $12.5 billion, and analysts have a "Moderate Buy" consensus rating with an average price target of $25.44.
Here’s Why Elanco Animal Health Incorporated (ELAN) Declined in Q4
This article analyzes why Elanco Animal Health Incorporated (ELAN) experienced a decline in Q4. It likely delves into the financial performance, market conditions, and other factors contributing to the company's drop during that quarter.
ELANCO ANIMAL HEALTH INC - DAVID HOOVER RETIRES FROM ELANCO BOARD (NOT AS 'CHAIRMAN')
David Hoover has announced his retirement from the Elanco Animal Health board, specifically as a board member and not as the chairman. This announcement comes amidst other board updates for Elanco, including the non-reelection of Deborah Kochevar and a reduction in the board size to nine members. Wall Street analysts currently forecast a positive outlook for ELAN stock, with several issuing "Buy" ratings and raising price targets.
Here’s Why Elanco Animal Health Incorporated (ELAN) Declined in Q4
This article from MSN provides a financial analysis of why Elanco Animal Health Incorporated (ELAN) experienced a decline in the fourth quarter. It is expected to delve into specific factors that contributed to the company's performance during that period.
DDD Partners LLC Acquires 108,941 Shares of Elanco Animal Health Incorporated $ELAN
DDD Partners LLC increased its stake in Elanco Animal Health (NYSE:ELAN) by 6.6% in Q3, now owning 1,753,369 shares valued at $35.31 million. Institutional ownership of Elanco is high at 97.48%, and insiders, including the CFO and a director, have recently bought shares. Analysts have a "Moderate Buy" rating for Elanco with an average target of $25.44, while the company trades near $25.15 with a market cap of $12.5 billion and a P/E ratio of 419.3.
Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of "Moderate Buy" by Brokerages
Elanco Animal Health (NYSE:ELAN) has received a "Moderate Buy" consensus rating from twelve analysts, with an average 12-month price target of $25.44, and some firms raising targets to $30. Insiders have recently increased their holdings, purchasing 43,450 shares in the last 90 days. The stock is trading near its one-year high of $26.08, reflecting a high trailing P/E of 419.30, suggesting valuation is driven by growth expectations.
Elanco Animal Health Board Updates Leadership
Elanco Animal Health announced that R. David Hoover and Deborah Kochevar will not seek re-election at the 2026 Annual Meeting, leading to a shift in the company's governance structure. Hoover served as Chairman since the 2018 IPO, while Kochevar led the Innovation, Science, and Technology committee. Following their departures, the board will consist of nine members, potentially impacting strategic direction and decision-making within the company.
Elanco Announces Updates to Board of Directors
Elanco Animal Health Incorporated (NYSE: ELAN) has announced changes to its Board of Directors. R. David Hoover and Deborah Kochevar will not seek re-election at the upcoming 2026 Annual Meeting of Shareholders in May, with Hoover retiring after serving as the first Chairman since the company's IPO and Kochevar concluding her distinguished service. The board will subsequently consist of nine directors.
Elanco Announces Updates to Board of Directors
Elanco Animal Health Incorporated announced that R. David Hoover and Deborah Kochevar will not seek re-election to the Board of Directors at the upcoming 2026 Annual Meeting of Shareholders in May. Hoover, the founding Chairman, is retiring after guiding Elanco through its spin-off and early years, while Kochevar is recognized for her leadership in the Innovation, Science and Technology committee. Following their departures, the Board will comprise nine directors.
State of Michigan Retirement System Invests $2.38 Million in Elanco Animal Health Incorporated $ELAN
The State of Michigan Retirement System recently purchased 118,300 shares of Elanco Animal Health (NYSE:ELAN), valued at approximately $2.38 million. This new stake comes as several other institutional investors have also adjusted their holdings in the company. Analyst sentiment for Elanco is generally positive, with a "Moderate Buy" consensus and UBS raising its price target to $30.00, alongside recent insider buying activity from the CEO and another executive.
Wesbanco Bank Inc. Has $1.79 Million Stake in Elanco Animal Health Incorporated $ELAN
Wesbanco Bank Inc. decreased its stake in Elanco Animal Health Incorporated by 40.6% in the third quarter, reducing its holdings to 89,000 shares valued at $1.79 million. Despite this, other institutional investors increased their positions, and insider buying by CEO Jeffrey N. Simmons and director Lawrence Kurzius indicates confidence. Analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $25.44, as the stock trades near its 52-week high.
Skylands Capital LLC Lowers Stock Holdings in Elanco Animal Health Incorporated $ELAN
Skylands Capital LLC significantly reduced its stake in Elanco Animal Health Incorporated by 31.9% in Q3, selling 138,450 shares but still retaining 295,200 shares valued at approximately $5.95 million. Despite this, institutional investors collectively own a substantial 97.48% of ELAN. The article also notes recent insider buying, including purchases by the CFO and another executive, totaling 43,450 shares worth about $937,883 over the past 90 days.
Animal Vaccine Market to Reach US$ 30.48 Billion by 2033 at 7.1%
The global animal vaccine market, valued at US$ 16.28 billion in 2024, is projected to reach US$ 30.48 billion by 2033, demonstrating an 8.6% CAGR, driven by increasing prevalence of infectious diseases, advancements in vaccine technology, and rising awareness of zoonotic risks. North America currently leads the market with a 35% share, followed by Europe and Asia Pacific, with key players including Zoetis, Merck, and Boehringer Ingelheim. The market is segmented by product type (modified live attenuated, inactivated, recombinant, toxoid), animal type (livestock, companion, aquaculture), and route of administration (subcutaneous, intramuscular, intranasal).
Companion Animal Healthcare Market Is Going to Boom | Major
A new study by HTF MI Research evaluates the global Companion Animal Healthcare Market, projecting its size, trends, and forecast to 2033. The market, driven by rising pet ownership and humanization, includes pharmaceuticals, diagnostics, vaccines, and preventive care. Key players like Zoetis, Elanco, and Merck Animal Health are covered, with North America dominating and Asia-Pacific emerging as the fastest-growing region.
Here's What the Street Thinks About Elanco Animal Health Incorporated (ELAN)
Elanco Animal Health Incorporated (ELAN) has garnered positive attention from analysts, receiving multiple rating upgrades and price target increases in January. BofA, UBS, and Piper Sandler all raised their price targets and maintained or upgraded their ratings, citing stronger operational results and the company's inroads with corporate groups. The company, which specializes in animal health products for pets and farm animals, is seen as a strong investment, although the article suggests other AI stocks might offer greater upside.
Principal Financial Group Inc. Acquires 1,245,631 Shares of Elanco Animal Health Incorporated $ELAN
Principal Financial Group Inc. significantly increased its stake in Elanco Animal Health, purchasing over 1.2 million shares to bring its total holdings to 1.26 million shares, valued at approximately $25.5 million. This comes as Elanco reported strong Q3 earnings, beating analyst estimates with $0.19 EPS and $1.14 billion in revenue. Insider transactions also show purchases by Rajeev A. Modi and Director Lawrence Erik Kurzius, while analysts maintain a "Moderate Buy" rating with an average price target of $25.44.
Elanco Animal Health Inc (ELAN) Stock Price Up 3.16% on Feb 5
Shares of Elanco Animal Health Inc (ELAN) increased by 3.16% on February 5th, reaching an intraday high of $25.39 before closing at $25.17. The stock is 0.85% below its 52-week high and significantly above its 52-week low. Wall Street analysts predict an average target price of $26.46, indicating an "Outperform" status, although GuruFocus estimates a GF Value of $14.26, suggesting a potential downside.
Hardman Johnston Global Equity Strategy initiated a position in Elanco Animal Health (ELAN)
The investment firm Hardman Johnston Global Equity Strategy has initiated a new position in Elanco Animal Health (ELAN). This move indicates a new investment focus or confidence in the animal health company. Further details on the size or rationale behind this position were not provided.
Independent Advisor Alliance Purchases 76,920 Shares of Elanco Animal Health Incorporated $ELAN
Independent Advisor Alliance significantly increased its stake in Elanco Animal Health (NYSE:ELAN) by 364.5% in Q3, now owning 98,025 shares worth approximately $1.974 million. Multiple institutional investors have also adjusted their positions in ELAN. Additionally, company insiders, including the CEO and a Director, recently purchased shares, totaling 43,450 shares worth $937,883, demonstrating insider confidence.
Bank of America Securities Sticks to Their Buy Rating for Elanco Animal Health (ELAN)
Bank of America Securities reiterated a Buy rating on Elanco Animal Health (ELAN) with a price target of $28.00, citing analyst Michael Ryskin's positive outlook. Despite this, another firm downgraded ELAN to a Hold on the same day. The company reported $1.14 billion in quarterly revenue and a GAAP net loss of $34 million for the quarter ending September 30, with positive corporate insider sentiment evidenced by recent share purchases.
Mitsubishi UFJ Trust & Banking Corp Takes $1.44 Million Position in Elanco Animal Health Incorporated $ELAN
Mitsubishi UFJ Trust & Banking Corp has established a new position in Elanco Animal Health (NYSE:ELAN), acquiring 71,674 shares valued at approximately $1.44 million during the third quarter. This move contributes to Elanco's substantial institutional ownership of 97.48%, with other investors also adjusting their stakes. The company is rated a "Moderate Buy" by analysts with a target price of $25.44, and corporate insiders, including the CEO and CFO, have recently increased their holdings in Elanco.
Federated Hermes Inc. Grows Stock Position in Elanco Animal Health Incorporated $ELAN
Federated Hermes Inc. increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 9.1% during the third quarter, now holding 2,379,391 shares valued at approximately $47.9 million. The company has an average "Moderate Buy" rating from analysts with a consensus target price of $25.11, and insiders have been purchasing shares, totaling $937,883 over the last ninety days. Elanco also recently beat quarterly EPS estimates and provided positive FY2025 guidance, with shares trading near their 52-week high.
Great Lakes Advisors LLC Takes $9.42 Million Position in Elanco Animal Health Incorporated $ELAN
Great Lakes Advisors LLC has acquired a new stake of 467,485 shares in Elanco Animal Health (NYSE:ELAN), valued at approximately $9.42 million. This investment comes as Elanco reported stronger-than-expected financial results, with institutional investors showing increased interest and company insiders also purchasing shares. Elanco's stock is currently trading up, backed by positive analyst reports and solid financial metrics.
UBS Group Forecasts Strong Price Appreciation for Elanco Animal Health (NYSE:ELAN) Stock
UBS Group has increased its price target for Elanco Animal Health (NYSE:ELAN) to $30 from $27, maintaining a "buy" rating and forecasting a 24.8% upside. This follows Elanco's strong quarterly performance, where it exceeded EPS and revenue estimates and issued positive FY2025 guidance. Insider buying and significant institutional ownership also indicate confidence in the company.
Universal Beteiligungs und Servicegesellschaft mbH Has $6.10 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN
Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in Elanco Animal Health Incorporated by 21.8% in Q3, now owning 302,804 shares valued at $6.10 million. Despite Universal's trimming, several insiders, including Director Lawrence Kurzius and CEO Jeffrey Simmons, have recently purchased significant shares. The company also reported strong quarterly results, beating EPS and revenue estimates, and received a "Moderate Buy" consensus rating from analysts with an average price target of $25.11.
Estate Counselors LLC Makes New $4.24 Million Investment in Elanco Animal Health Incorporated $ELAN
Estate Counselors LLC has made a new investment of $4.24 million in Elanco Animal Health Incorporated, acquiring 210,633 shares. This makes institutional investors own 97.48% of the company's stock, with analysts largely maintaining a "Moderate Buy" rating and an average price target of $25.11. Corporate insiders have also been increasing their stakes, and the company recently surpassed EPS estimates and issued positive FY2025 guidance.
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) announced it will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. The company will also host a conference call on the same day at 8:00 a.m. Eastern Standard Time for investors, media, and the public to discuss its performance. A live webcast and replay will be available on Elanco's investor relations website.
Piper Sandler Upgrades Elanco Animal Health (ELAN) to Overweight with $30 Price Target
Piper Sandler has upgraded Elanco Animal Health (ELAN) from "neutral" to "overweight" and increased its price target to $30, citing significant progress in corporate accounts. This upgrade suggests strong market share growth for Elanco, in contrast to Zoetis (ZTS) which was downgraded due to challenges in consumer spending and an innovation gap. The report highlights Elanco's potential for price increases on its core products and a positive outlook from analysts.
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
Elanco Animal Health Incorporated will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. The company will host a conference call at 8:00 a.m. Eastern Standard Time for investors and media to discuss its performance. A live webcast and replay will be available on Elanco's investor relations website.
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
Elanco Animal Health Incorporated announced it will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. The company will also host a conference call on the same day at 8:00 a.m. EST for investors, media, and the public, accessible via webcast on Elanco's investor relations website. A replay of the call will also be available on the website.
This Elanco Animal Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Several top Wall Street analysts have upgraded their ratings for five major companies. Sphere Entertainment Co., Topgolf Callaway Brands Corp., Datadog Inc., Elanco Animal Health Inc., and Alphabet Inc. all received upgrades from various financial institutions, indicating a more bullish outlook on their stock performance. The upgrades came with revised price targets for each stock, reflecting analysts' updated expectations.
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) announced it will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. The company will also host a conference call on the same day at 8:00 a.m. Eastern Standard Time to discuss its performance. Investors, media, and the public can access a live webcast and replay of the call via Elanco's investor relations website.
Elanco Animal Health Incorporated $ELAN Shares Acquired by Amalgamated Bank
Amalgamated Bank significantly increased its stake in Elanco Animal Health Incorporated (NYSE: ELAN) by 793.7% in Q3, now holding 226,580 shares valued at $4.56 million. Elanco recently surpassed quarterly EPS and revenue expectations and has set optimistic FY2025 guidance, with its stock trading near its 52-week high. Company insiders have also been actively purchasing shares, while institutional investors collectively own nearly 97.48% of the company's stock.
Pet Pharmaceuticals Market Is Booming Worldwide 2026-2033 | Zoetis • Merck Animal Health • Elanco Animal Health
Coherent Market Insights has published a report titled "Pet Pharmaceuticals Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033". The report analyzes market competition, geographic distribution, and growth potential, providing comprehensive insights into industry performance, key success factors, risk assessment, and financial projections. It includes major players like Zoetis, Merck Animal Health, and Elanco Animal Health, and segments the market by animal type and product category.
Animal Health Market Overview and Leading Players: Bayer, Ceva
The animal health market is experiencing significant growth driven by increasing awareness of animal welfare, technological advancements, and strategic partnerships. Key players like Bayer, Ceva Santé Animale, Elanco Inc., and Merck Ltd. are innovating in pharmaceuticals, vaccines, and diagnostics. The market is segmented by product type (pharmaceuticals, medicinal feed additives, vaccines, diagnostics) and application (companion and production animals), with substantial opportunities in telemedicine and advanced diagnostics despite regulatory challenges.
Elanco Animal Health (NYSE:ELAN) Hits New 1-Year High on Analyst Upgrade
Elanco Animal Health (NYSE:ELAN) reached a new 52-week high after Wall Street Zen upgraded its rating from "buy" to "strong-buy." The company also saw significant insider buying from its CEO and a director, along with strong institutional ownership. Elanco beat its Q3 earnings estimates and provided optimistic FY2025 guidance.
Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Recommendation of "Moderate Buy" by Analysts
Thirteen analysts collectively recommend a "Moderate Buy" for Elanco Animal Health (NYSE: ELAN), setting an average 12-month price target of $23.78. Recent insider buying by senior executives, totaling $937,883 in the last three months, indicates increased insider confidence. The company also reported strong Q3 earnings, beating EPS and revenue expectations, and provided optimistic FY2025 guidance.
Poultry Antibiotic Market Is Booming Worldwide 2026-2033
The global Poultry Antibiotic Market is projected to grow from USD 2.25 billion in 2025 to USD 3.38 billion in 2032, with a compound annual growth rate (CAGR) of 6%. This growth is driven by rapid innovation, increasing investments, and shifting regional dynamics. The report provides a comprehensive analysis, including market segmentation by product type, administration mode, distribution channel, and key players like Zoetis Inc. and Elanco Animal Health.
Nisa Investment Advisors LLC Lowers Stock Holdings in Elanco Animal Health Incorporated $ELAN
Nisa Investment Advisors LLC significantly reduced its stake in Elanco Animal Health Incorporated by 67.4% in the third quarter of 2025, selling 89,352 shares and retaining 43,308 shares valued at $872,000. Despite this, Elanco Animal Health beat Q3 earnings and revenue expectations and provided optimistic FY2025 guidance. Insider activity showed notable buying from CFO Robert Vanhimbergen and Rajeev A. Modi, with insiders purchasing a total of 43,450 shares, increasing insider ownership to 0.89%.
